PL3283634T3 - Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem - Google Patents
Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotoremInfo
- Publication number
- PL3283634T3 PL3283634T3 PL16719791T PL16719791T PL3283634T3 PL 3283634 T3 PL3283634 T3 PL 3283634T3 PL 16719791 T PL16719791 T PL 16719791T PL 16719791 T PL16719791 T PL 16719791T PL 3283634 T3 PL3283634 T3 PL 3283634T3
- Authority
- PL
- Poland
- Prior art keywords
- transgenes
- recombinant adenovirus
- adenovirus expressing
- bidirectional promoter
- bidirectional
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title 1
- 230000002457 bidirectional effect Effects 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
- C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/60—Vectors comprising a special translation-regulating system from viruses
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562147453P | 2015-04-14 | 2015-04-14 | |
EP15163538 | 2015-04-14 | ||
EP16719791.2A EP3283634B1 (en) | 2015-04-14 | 2016-04-12 | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
PCT/EP2016/057982 WO2016166088A1 (en) | 2015-04-14 | 2016-04-12 | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3283634T3 true PL3283634T3 (pl) | 2019-10-31 |
Family
ID=52875030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16719791T PL3283634T3 (pl) | 2015-04-14 | 2016-04-12 | Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem |
Country Status (9)
Country | Link |
---|---|
US (1) | US10570417B2 (pl) |
EP (1) | EP3283634B1 (pl) |
JP (1) | JP6735288B2 (pl) |
CN (1) | CN107466324B (pl) |
AU (1) | AU2016249798B2 (pl) |
CA (1) | CA2981841A1 (pl) |
PL (1) | PL3283634T3 (pl) |
SI (1) | SI3283634T1 (pl) |
WO (1) | WO2016166088A1 (pl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109154000B (zh) * | 2016-05-12 | 2022-07-05 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
AU2017283118B2 (en) | 2016-06-20 | 2019-02-07 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
AU2018217935B2 (en) | 2017-02-09 | 2020-04-30 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
CN108424934A (zh) * | 2018-04-16 | 2018-08-21 | 和元生物技术(上海)股份有限公司 | 一种慢病毒cag-cmv双启动子改造载体构建及应用 |
US11713469B2 (en) * | 2018-07-20 | 2023-08-01 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing Zika antigen with improved productivity |
EP4054611A4 (en) * | 2019-11-06 | 2023-12-06 | Memgen, Inc. | ONCOLYTIC ADENOVIRUS WITH ENHANCED REPLICATION |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
BR9710030A (pt) | 1996-07-01 | 1999-08-10 | Rhone Poulenc Rorer Sa | Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
JP4358434B2 (ja) | 1998-02-17 | 2009-11-04 | シェーリング コーポレイション | ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法 |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1133316B1 (en) | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
PT1818408E (pt) | 1999-05-17 | 2011-11-15 | Crucell Holland Bv | Adenovírus recombinante do serótipo ad11 |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US7468181B2 (en) | 2002-04-25 | 2008-12-23 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
CA2378539A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
EP1083227A1 (en) * | 1999-08-24 | 2001-03-14 | Universite Libre De Bruxelles | Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
US20020041884A1 (en) | 2000-03-07 | 2002-04-11 | Evans Robert K. | Adenovirus formulations |
EP1320621A4 (en) | 2000-09-15 | 2005-11-23 | Merck & Co Inc | ADVANCED FIRST-GENE ADENOVIRAL VACCINES EXPRESSING CODON OPTIMIZATION OF THE GAG, POL AND NEF PROTEINS OF HIV-1 AND CHANGES THEREOF |
CN1177042C (zh) * | 2001-04-12 | 2004-11-24 | 上海华康生物技术有限公司 | 共表达人p53基因和人细胞因子基因的重组腺病毒及其制法和用途 |
EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
IL162404A0 (en) | 2002-01-18 | 2005-11-20 | Schering Ag | Stabilized formulations of adenovirus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
NZ534865A (en) | 2002-04-25 | 2008-07-31 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
DK1506287T3 (da) | 2002-05-14 | 2007-08-20 | Merck & Co Inc | Fremgangsmåder til oprensning af adenovirus |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
CA2496918A1 (en) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
GB0223696D0 (en) * | 2002-10-14 | 2002-11-20 | Ml Lab Plc | Improved immunotherapy |
WO2004037294A2 (en) | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
NZ539813A (en) | 2002-12-17 | 2008-04-30 | Crucell Holland Bv | A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6 |
SI1601776T1 (sl) * | 2003-03-11 | 2008-10-31 | Serono Lab | Ekspresijski vektorji, ki vsebujejo mcmv ie2 promotor |
DK1616012T3 (da) * | 2003-04-24 | 2008-04-21 | San Raffaele Centro Fond | Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2880061C (en) | 2004-01-23 | 2018-03-13 | Agostino Cirillo | Chimpanzee adenovirus vaccine carriers |
WO2005080556A2 (en) | 2004-02-23 | 2005-09-01 | Crucell Holland B.V. | Virus purification methods |
CA2585523A1 (en) * | 2004-11-02 | 2006-05-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof |
SG159554A1 (en) | 2004-11-16 | 2010-03-30 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
CA2593429A1 (en) * | 2004-12-02 | 2006-06-08 | Laboratoires Serono S.A. | The lupac bifunctional marker and its use in protein production |
DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
KR101451620B1 (ko) | 2005-05-12 | 2014-10-21 | 글락소 그룹 리미티드 | 백신 조성물 |
WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
EP1969144A2 (en) * | 2005-12-16 | 2008-09-17 | The Uab Research Foundation | Compositions and methods related to controlled gene expression using viral vectors |
JP5016614B2 (ja) | 2006-02-28 | 2012-09-05 | バクサート インコーポレーティッド | キメラアデノウイルスベクター |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
WO2007110409A1 (en) | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
WO2008074189A1 (fr) * | 2006-12-20 | 2008-06-26 | Shenzhen Well.D Genetic Engineering Co., Ltd | Adénovirus recombinant comprenant un gène khp50 recombinant et son procédé de préparation et ses utilisations |
WO2009026183A1 (en) | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Use of chimeric hiv/siv gag proteins to optimize vaccine-induced t cell responses against hiv gag |
WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
JP5882741B2 (ja) | 2009-02-02 | 2016-03-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用 |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
JP5465331B2 (ja) | 2009-10-15 | 2014-04-09 | クルセル ホランド ベー ヴェー | 高細胞密度の培養物からのアデノウイルスの精製方法 |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
SG11201405803PA (en) | 2012-03-22 | 2014-11-27 | Crucell Holland Bv | Vaccine against rsv |
-
2016
- 2016-04-12 EP EP16719791.2A patent/EP3283634B1/en active Active
- 2016-04-12 CA CA2981841A patent/CA2981841A1/en active Pending
- 2016-04-12 SI SI201630306T patent/SI3283634T1/sl unknown
- 2016-04-12 CN CN201680021713.3A patent/CN107466324B/zh active Active
- 2016-04-12 PL PL16719791T patent/PL3283634T3/pl unknown
- 2016-04-12 JP JP2017553927A patent/JP6735288B2/ja active Active
- 2016-04-12 US US15/566,073 patent/US10570417B2/en active Active
- 2016-04-12 AU AU2016249798A patent/AU2016249798B2/en active Active
- 2016-04-12 WO PCT/EP2016/057982 patent/WO2016166088A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA2981841A1 (en) | 2016-10-20 |
AU2016249798A1 (en) | 2017-11-30 |
JP2018512158A (ja) | 2018-05-17 |
AU2016249798B2 (en) | 2022-05-26 |
CN107466324A (zh) | 2017-12-12 |
SI3283634T1 (sl) | 2019-08-30 |
EP3283634A1 (en) | 2018-02-21 |
EP3283634B1 (en) | 2019-05-22 |
JP6735288B2 (ja) | 2020-08-05 |
US10570417B2 (en) | 2020-02-25 |
CN107466324B (zh) | 2022-01-14 |
WO2016166088A1 (en) | 2016-10-20 |
US20180135075A1 (en) | 2018-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1246341A1 (zh) | 採用重組李斯特氏菌株的聯合治療 | |
IL258044A (en) | Oncolytic adenovirus encoding the b7 protein | |
HK1213292A1 (zh) | 組成型启動子 | |
HK1251256A1 (zh) | 启動子變體 | |
SI3283634T1 (sl) | Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem | |
IL268291A (en) | Multiple transgene recombinant adenovirus | |
SG11201606905YA (en) | Fibers with filler | |
EP3610025A4 (en) | MULTIPLE TRANSGENIC RECOMBINANT ADENOVIRUS | |
IL275553A (en) | Surfboard with overlap | |
SG11201610051YA (en) | Ghrelin secretion promoter | |
SI3390620T1 (sl) | Fuzijske variante polipeptida z izboljšanimi lastnostmi, povezane z omega-hidroksilazo | |
ZA201608054B (en) | Synthetic promoter construct for transgene expression | |
GB2553170B (en) | Promoter | |
PL3087179T3 (pl) | Polipeptydy fuzyjne związane z omega-hydroksylazą o ulepszonych właściwościach | |
ZA201702208B (en) | Recombinant promoter with increased fiber-specific expression | |
LT3283634T (lt) | Rekombinantinis adenovirusas, ekspresuojantis du transgenus su dvikrypčiu promotoriumi | |
GB2522910B (en) | Thread issue control | |
PL3085557T3 (pl) | Jednostka wzmacniająca | |
PT3103607T (pt) | Máquina de corte de cerâmica com guia de ângulo dupla | |
GB2524028B (en) | A sensor unit with a tilting sensor head | |
GB2533685B (en) | Agrochemical composition with polyether adhesion promoter | |
GB201300529D0 (en) | Recombinant polypeptide |